Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.66 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.66 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.61 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.61 |
| ▸ | ITGAV | P06756 | 4/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639190 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL19661136 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL19678647 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL17833024 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL19678622 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL23519701 | 1.00 | ITGB1 (0.66) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL21955605 | 0.99 | ITGB1 (0.65) | ITGB1ITGA5ITGA4ITGB7ITGAV | |
| SCHEMBL23519439 | 0.92 | ITGB1 (0.56) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL19639216 | 0.92 | ITGB1 (0.56) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL19639217 | 0.92 | ITGB1 (0.56) | ITGB1ITGA5ITGA4ITGB7ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | claimed |
| JP-2002512625-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250319200-A1 | ADENOVIRAL GENE THERAPY VECTORS | ENSOMA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12419619-B2 | Aspiration device | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250135039-A1 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | FRED HUTCHINSON CANCER CENTER | 2025-05-01 | — | — | US | disclosed |
| US-20250082777-A1 | METHODS OF EX VIVO DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | SANA BIOTECHNOLOGY, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20240368582-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | ENSOMA, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4360567-A2 | ASPIRATION DEVICE | Yale University (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2018152371-A1 | IN VIVO GENE THERAPY FOR IMMUNE DEFICIENCIES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20170348375-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | COMMW SCIENT IND RES ORG (AU) | 2017-12-07 | — | — | US | disclosed |
| US-20170348375-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | COMMW SCIENT IND RES ORG (AU) | 2017-12-07 | — | — | US | disclosed |
| US-20170340693-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-11-30 | — | — | US | disclosed |
| US-20170340693-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-11-30 | — | — | US | disclosed |
| CN-107405331-A | Migrated using the integrin antagonists of α 9 from stem cell tabernacle and discharge HSC | 联邦科学和工业研究组织 | 2017-11-28 | — | — | CN | disclosed |
| CN-107206085-A | Use α9The HSC of integrin antagonists and CXCR4 antagonists migration and release | 联邦科学和工业研究组织 | 2017-09-26 | — | — | CN | disclosed |
| WO-2016090403-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348375-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | CXCL12, BST2, CCR9 | ITGB1 6/4885ITGA5 19/4885ITGA4 26/4885 |
| US-20170340693-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | CXCL12, CXCR4, CCR9 | ITGB1 8/4885ITGA5 20/4885ITGA4 42/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | ITGB1 27/4885ITGA5 81/4885ITGA4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.